| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| ln Vitro |
4-Vinylcyclohexene dioxide (90 μM-3 mM; 24 h) can induce apoptosis in human ovarian granulosa cell line (SVOG), increase intracellular reactive oxygen species, and inhibit their proliferation [2]. 4-Vinylcyclohexene dioxide (10 nM-10 mM; 6-24 h) can promote the activation of primordial follicles by transiently activating the PI3K/Akt/mTOR pathway [3].
|
|---|---|
| ln Vivo |
4-Vinylcyclohexene dioxide (80 mg/kg; intraperitoneal injection; once daily for 1–15 days) can accelerate follicular atresia by activating the caspase cascade in the small preantral follicles of female F344 rats[1]. 4-Vinylcyclohexene dioxide (80 mg/kg; intraperitoneal injection; once daily for 5–10 days) can promote superovulation in middle-aged C57BL/6J mice, increase serum estradiol (E2) and follicle-stimulating hormone (FSH) levels, and enhance follicular development[3]. 4-Vinylcyclohexene dioxide (100–500 mg/kg; oral administration; once daily for 28 days) can disrupt sperm characteristics in male Wistar rats, reduce reproductive hormone levels, and induce oxidative stress and apoptosis in the testes and epididymis[6].
|
| Cell Assay |
Apoptosis analysis [2]
Cell Types: Human ovarian granulosa cell line (SVOG) Tested Concentrations: 0.5 mM, 1 mM Incubation Duration: 24 hours Experimental Results: The number of Annexin V positive cells increased, and apoptosis increased. The number of Hoechst 33342 and PI positive cells increased significantly in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models:Female F344 rats (28 days old) [1]
Doses: 80 mg/kg Route of Administration: Intraperitoneal injection, day 1 or day 15 Experimental Results: Cytoplasmic caspase-3 activity increased in small follicles (day 1: 2.86; day 15: 3.25, VCD/control group). Proceaspase-3 protein increased by 212% (day 15). Caspase-8 activity increased (day 15). Caspase-9 activity increased (day 1). |
| References |
|
| Molecular Formula |
C8H12O2
|
|---|---|
| Molecular Weight |
140.18
|
| CAS # |
106-87-6
|
| Related CAS # |
4-Vinylcyclohexene dioxide (Standard)
|
| Appearance |
Colorless to light yellow liquid (Density: 1.0986 g/cm3)
|
| SMILES |
C1(C2CCC3OC3C2)CO1
|
| Synonyms |
Vinylcyclohexene diepoxide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~356.68 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (35.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (35.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (35.67 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. Solubility in Formulation 4: 25 mg/mL (178.34 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution; Need ultrasonic. Solubility in Formulation 5: 25 mg/mL (178.34 mM) in 15% Cremophor EL + 85% Saline (add these co-solvents sequentially from left to right, and one by one), Suspended solution; Need ultrasonic. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1337 mL | 35.6684 mL | 71.3369 mL | |
| 5 mM | 1.4267 mL | 7.1337 mL | 14.2674 mL | |
| 10 mM | 0.7134 mL | 3.5668 mL | 7.1337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
